The Psoriasis Drugs Clinical Pipeline 2020​


​Release Date: Q2' 2020
Number of Candidates: 76

Synopsis: A chronic inflammatory disorder of the skin, psoriasis impacts over 125 million people worldwide and nearly 7.5 million in the United States. The main symptoms are thick visibly reddened scaly patches of skin which cause itching and pain. Although psoriasis is not a life-threatening disease, it is associated with significant physical, psychosocial, and economic burdens corresponding to disease severity.  
​
The need for treatment is lifelong, aimed at remission by preventing skin cells from growing rapidly and reducing inflammation. Treatment is determined by the type, area of skin affected and severity of psoriasis in a patient. Mild psoriasis can largely be treated with topical therapies, while moderate-to-severe psoriasis is treated with oral systemics, biologics or a combination therapy. 
Drug developers are continuing to invest heavily in drug development programs for psoriasis. New drug development programs for psoriasis are largely based on TNF-alpha inhibitors and selective inhibition of interleukins including IL-12, IL-17, and IL-23. Other programs include but are not limited to PD-L1 (Programmed Death Ligand-1) antibodies; topical treatments such as JAK (Janus Kinase) inhibitors, TYIs (Tyrosine Kinase Inhibitors) and PDE-4 (Phosphodiesterase-4) inhibitors; VDR (Vitamin D Receptors); and new combination therapies, with several novel drugs in late-stage development. ​

The “Psoriasis Drugs Pipeline 2020” excel sheet presents a look at the major drug candidates currently in the clinical pipeline. 

The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the psoriasis market, profiling 76 future candidates.

For a Sample and Inquiries please contact [email protected]

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories:
  • Candidate (Name)
  • Developer(s)
  • Therapeutic Area(s)​
    • ​Plaque Psoriasis 
    • Psoriatic Arthritis
    • Other
  • Mechanism of Action(s)
    • TNF Inhibitors
    • Interleukin Inhibitors
    • PDE4 inhibitors
    • JAK Inhibitors
    • VDR
    • NR1l3
    • Others
  • Route Of Administration​
    • ​Oral
    • Topical
    • Parenteral
  • Phase
    • Pre-Clinical
    • ​Phase I
    • Phase I/II
    • Phase II
    • Phase III
    • Pre-Registration
    • Registered

List of Companies Mentioned:
The following companies and organizations have been mentioned in the pipeline:
Abbott Laboratories
AbbVie
AbGenomics
Aclaris Therapeutics
Affibody
Akros Pharma
Alder BioPharmaceuticals
Alvotech
Amgen
AnaptysBio
Arcutis
AstraZeneca
Azitra
Bayer Pharmaceuticals
Beijing Wenfeng Tianji Pharmaceuticals
Biocad
Biocon
BioMimetix
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Boston Pharmaceuticals
Botanix Pharmaceuticals
Cadila Pharmaceuticals
Can-Fite BioPharma
Celgene Corporation
Celltrion
Cipher Pharmaceuticals
Coherus BioScience
Creabilis SA
Cutanea
Dermavant Sciences
Dr Reddys Laboratories
Eli Lilly and Company
Escalier Biosciences
Evelo Biosciences
Exicure
Forward Pharma
Galapagos NV
Galectin Therapeutics
Gilead Sciences
GSK (GlaxoSmithKline)
Hanwha Chemical
Immune Pharmaceuticals
Innovation Pharmaceuticals
Japan Tobacco 
Jiangsu Hengrui Medicine
Kadmon Holdings
LEO Pharma
Lipidor
Lycera
Maruho Company
MC2 Therapeutics
Merck
Mylan
Novan
Novartis
Pfizer
Photogen Technologies Inc.
Polichem (Almirall)
Provectus Biopharmaceuticals
Quotient Sciences
Samumed
Sandoz
Sanofi
Santalis Healthcare
Sienna Biopharmaceuticals
Sun Pharmaceutical 
UCB
Vitaeris
Welichem Biotech
XBiotech
XenoPort
Ziarco